French Court Denies Roche Action Over Avastin In AMD
This article was originally published in SRA
Executive Summary
A judge at France's top administrative court, the Conseil d'Etat, has denied a request from Roche to suspend the government's decision to reimburse its anticancer, Avastin (bevacizumab), for the off-label indication of wet age-related macular degeneration (AMD)1.
You may also be interested in...
Roche, Novartis Lose French Court Battle Over Off-Label Use Of Avastin In AMD
Roche and Novartis have been unsuccessful in their attempt to stop the French authorities using Avastin off label in wet AMD for financial reasons.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.